Aspira Women's Health Files 8-K for Equity Sale

Ticker: AWHL · Form: 8-K · Filed: Mar 11, 2025 · CIK: 926617

Sentiment: neutral

Topics: equity-sale, definitive-agreement

TL;DR

Aspira Women's Health selling more stock, filing shows.

AI Summary

On March 5, 2025, Aspira Women's Health Inc. entered into a material definitive agreement related to unregistered sales of equity securities. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This filing indicates a potential capital raise or issuance of new shares, which could impact the company's financial structure and shareholder equity.

Risk Assessment

Risk Level: medium — Filings related to unregistered equity sales can indicate financial needs or strategic shifts that may carry inherent risks for investors.

Key Players & Entities

FAQ

What type of material definitive agreement was entered into by Aspira Women's Health Inc. on March 5, 2025?

The filing indicates a material definitive agreement related to unregistered sales of equity securities.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is Aspira Women's Health Inc.

In which state is Aspira Women's Health Inc. incorporated?

Aspira Women's Health Inc. is incorporated in Delaware.

What were some of the former names of Aspira Women's Health Inc.?

Some of the former names of Aspira Women's Health Inc. include Vermillion, Inc., Ciphergen Biosystems Inc, and Abiotic Systems.

What is the business address of Aspira Women's Health Inc.?

The business address is 12117 Bee Caves Road, Building Three, Suite 100, Austin, TX 78738.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding Aspira Women's Health Inc. (AWHL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing